Areas of Interest & Competitive Research Grants - Bristol Myers Squibb
Areas of Interest (AOI)
Bristol Myers Squibb seeks Independent Research applications across all therapeutic areas. Our Areas of Interest outline additional criteria to help guide the scientific community. All concept applications submitted that best align with our interests will be considered and evaluated.
| Therapeutic Area and / or Compound | AOIs Posted on BMS.com | Pre-Concept Submission Period | |
| Start Date | End date | ||
| Immunology – (ozanimod) Multiple Sclerosis | 22-Nov-21 | 3-Jan-22 | 14-Jan-22 |
| Immunology – (abatacept) | 1-Nov-21 | 13-Dec-21 | 14-Jan-22 |
| Immunology – (ozanimod) Ulcerative colitis | 1-Nov-21 | 1-Nov-21 | 24-Dec-21 |
| Immunology – TYK2 (deucravacitinib) | 20-Sep-21 | 18-Oct-21 | 19-Nov-21 |
| Oncology – Relatlimab | 15-Sept-21 | 4-Oct-21 | 29-Oct-21 |
| Hematology | 28-May-21 | 21-Jun-21 | 23-July-21 |
| Cardiovascular – (mavacamten) Hypertrophic Cardiomyopathy | 10-May-21 | 14-Jun-21 | 9-Jul-21 |
Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.
- If you are a potential investigator who is interested in seeking support to conduct independent research involving Nivolumab in Japan, Taiwan, or Korea, click here
- If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
- If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
- If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here
- If you are a potential investigator who is interested in seeking support for independent research involving NKTR-214 (Bempegaldesleukin) & Nivolumab, click here
Zeposia (ozanimod) ISR Areas of Interest RFP#1 - 2022: Multiple Sclerosis
In Scope:
Individuals with relapsing forms of MS (includes RIS, CIS, RRMS, active SPMS)
- Early treatment, including clinical benefits, treatment sequencing, response predictors
- Differentiation among available DMTs, including MS DMT comparisons and patient reported outcomes
- Management of ethnically and racially diverse patient population and/or MS comorbidities
- COVID-19 vaccine response/clinical outcomes
- Brain atrophy & cognition, including correlation of cognition and imaging, clinical relevance and patient centric approaches, cognitive phenotyping
- Artificial intelligence, in silico and/or digital biomarker models
- Central effects, including, axonal integrity/astrocyte biology
Out of scope:
- Pediatric studies
- Non-approved indications
- Combination with other disease modifying therapies
- Alternative dosing other than 0.92 mg QD
IMM- Orencia (abatacept) ISR Areas of Interest – 2021 RFP Cycle 2
- Early Rheumatoid Arthritis – Orencia
- How to define early Rheumatoid Arthritis
- How to define early intervention criteria
- Biomarker defined Rheumatoid Arthritis and Precision Medicine– Orencia
- Predictive and prognostic biomarkers
- Therapeutic risk benefit profiles:
- Efficacy and onset of action
- Long-term treatment: durability of response, safety
- Rheumatoid Arthritis co-morbidities – Orencia
- RA associated with cardio-vascular disease
- Therapeutic risk benefit profiles
- Predictive biomarkers
- RA associated with cardio-vascular disease
- Multi-organ high unmet medical need diseases – Orencia
- Rheumatologic diseases associated with Rheumatoid Arthritis and/or Auto-antibodies and T cell mediated diseases
Begin a New Application